Id |
Subject |
Object |
Predicate |
Lexical cue |
T312 |
0-36 |
Sentence |
denotes |
Adaptive Immune Response in COVID-19 |
T313 |
38-73 |
Sentence |
denotes |
Functional Adaptive Immune Response |
T314 |
74-178 |
Sentence |
denotes |
The functional but well-regulated adaptive immune response is necessary to overcome the viral infection. |
T315 |
179-423 |
Sentence |
denotes |
Specifically, T cells when recruited to the site of infection engage in eliminating the infected cells and act in concordance with virus-specific neutralization antibodies to provide sustained immunity (Hor et al., 2015; De Biasi et al., 2020). |
T316 |
424-750 |
Sentence |
denotes |
Considering the recent extensive work in understanding the functional early immune response during COVID-19, it appears that a complex interplay between T and B cell immune response along with patient-specific underlying health condition and genetic factors determines the recovery, as will be discussed in following sections. |
T317 |
752-767 |
Sentence |
denotes |
T Cell Response |
T318 |
768-981 |
Sentence |
denotes |
Generation of early adaptive immune response is critical for the selective elimination of virus-infected cells and neutralization of viral antigens, thereby preventing the damage to the underlying lung parenchyma. |
T319 |
982-1187 |
Sentence |
denotes |
Cytokines, chemokines, PAMPs, and DAMPs released by infected ATII and activated AMs in the lung are adequate to mount a well-coordinated and regulated adaptive immune response by priming lung resident DCs. |
T320 |
1188-1306 |
Sentence |
denotes |
After encountering the antigen-presenting DCs, naive CD4+ T cells differentiate into effector and memory CD4+ T cells. |
T321 |
1307-1529 |
Sentence |
denotes |
At least five different CD4+ T cell lineages are known (TH1, TH2, TH17, TFH, and TREG cells) with prominent roles of TH1 and TFH cells in mounting antiviral response during SARS-CoV infection (Channappanavar et al., 2014). |
T322 |
1530-1639 |
Sentence |
denotes |
Additionally, some studies have also shown a functional TH2 response in PBMCs derived from COVID-19 patients. |
T323 |
1640-1773 |
Sentence |
denotes |
Release of TH2 specific cytokines like IL-4 and IL-5 was observed in vitro after these cells were stimulated (Weiskopf et al., 2020). |
T324 |
1774-1921 |
Sentence |
denotes |
Similarly, these patients show enhanced production of IL-17 along with other TH17 cell-specific cytokines (Liu J. et al., 2020; Wu and Yang, 2020). |
T325 |
1922-2128 |
Sentence |
denotes |
These findings suggest that the TH cell response in COVID-19 patients is complex concerning other infections, and this complexity may partly depend upon the prevailing pathophysiological state of a patient. |
T326 |
2129-2293 |
Sentence |
denotes |
During viral infections like SARS-CoV, TH1 differentiation is influenced by IL-12 and IFN-γ secreted by DCs along with co-stimulatory signaling via B7-1/2 and CD28. |
T327 |
2294-2431 |
Sentence |
denotes |
Whereas IL-6 secreted by DCs influence TFH differentiation to aid in antibody secretion by B cells (Tang et al., 2008; Lau et al., 2012). |
T328 |
2432-2689 |
Sentence |
denotes |
Under the influence of chemokines (CCL3, CCL4, CCL5, CCL8), TH1 cells are recruited to the site of infection and are distinguished by the secretion of IL-2, IFN-γ, IL-12, and TNF-α as the main effector cytokines during SARS-CoV infections (Li et al., 2008). |
T329 |
2690-2861 |
Sentence |
denotes |
Similarly, naive CD8+ T cells are activated by DCs by engaging MHC-I and TCR receptors, along with CD28-B7 co-stimulatory signaling and cytokines released by CD4+ T cells. |
T330 |
2862-3010 |
Sentence |
denotes |
IL-2 secreted chiefly by CD4+ T cells is also implicated in their long-term maintenance and proliferation (Eickhoff et al., 2015; Hor et al., 2015). |
T331 |
3011-3187 |
Sentence |
denotes |
Notably, CD8+ T cells could also be activated independently of help from CD4+ T cells under conditions where a robust IFN Type I response is present (Wiesel and Oxenius, 2012). |
T332 |
3188-3404 |
Sentence |
denotes |
These activated CD8+ T cells [also referred to as cytotoxic T lymphocytes (CTLs)] get subsequently recruited to the effector organ under the influence of chemokines (CCL3, CCL4, CCL5, CXCL9, and CXCL10) (Nolz, 2015). |
T333 |
3405-3604 |
Sentence |
denotes |
At the infected site, CTLs mount an antiviral response by directly killing the infected cells via secretion of cytotoxic molecules like granzymes, perforins, granulysin, and other cytotoxic granules. |
T334 |
3605-3852 |
Sentence |
denotes |
Very recently, a study shows that CTLs secrete the granzymes and perforins as supramolecular attack particles (SMAPs) in a glycoprotein complex along with over 283 other proteins (including cytokines such as IFN-γ and TNF-α) (Bálint et al., 2020). |
T335 |
3853-3954 |
Sentence |
denotes |
It will be interesting to know whether infection by CoVs also influences the release of SMAP by CTLs. |
T336 |
3955-4096 |
Sentence |
denotes |
Animal studies have revealed the critical molecular insights of CD4+ cells in SARS-CoV clearance and attenuation of a pathological condition. |
T337 |
4097-4236 |
Sentence |
denotes |
The depletion of CD4+ cells was associated with reduced virus clearance and interstitial pneumonitis (Jin et al., 2005; Wang et al., 2006). |
T338 |
4237-4362 |
Sentence |
denotes |
In comparison, the adoptive transfer of virus-specific CD4+ and CD8+ T cells resulted in viral clearance (Zhao et al., 2010). |
T339 |
4363-4579 |
Sentence |
denotes |
Similarly, clinical data has consistently shown the presence of antigen-specific CD4+ and CD8+ T cells in the recovered patients, akin to what was found in immunized animals, reviewed in Channappanavar et al. (2014). |
T340 |
4580-4716 |
Sentence |
denotes |
On the other hand, severe cases of SARS-CoV infection were associated with a decline in T cells, as will be discussed in later sections. |
T341 |
4717-4890 |
Sentence |
denotes |
Thus, based on these animal and clinical data, CD4+ T and CD8+ T cells were central to the antiviral response during SARS-CoV infection (Peng et al., 2006; Oh et al., 2012). |
T342 |
4891-5006 |
Sentence |
denotes |
A subset of primed CD4+ and CD8+ T cells differentiates into long-acting memory cells after the infection subsides. |
T343 |
5007-5180 |
Sentence |
denotes |
TCR-p: MHCII signaling helps in CD4+ T memory cell formation along with presence of cytokines like IL-2, IL-21 and interaction via CD40R-CD40L (Jaigirdar and MacLeod, 2015). |
T344 |
5181-5328 |
Sentence |
denotes |
Similarly, This CD8+ T cell transition to memory cells take place under the influence of CD8+ TREG cells via secreted IL-10 (Laidlaw et al., 2015). |
T345 |
5329-5466 |
Sentence |
denotes |
Long lasting CD4+ and CD8+ T memory cells were detected in the recovered SARS-CoV infected patients (Peng et al., 2006; Li et al., 2008). |
T346 |
5467-5627 |
Sentence |
denotes |
Besides, other T cells subsets which are involved in antiviral response include unconventional NKT cells (CD56+) and MAIT (mucosa-associated invariant T) cells. |
T347 |
5628-5797 |
Sentence |
denotes |
NKT cells act at the interface between innate and adaptive immune response and traffic to the site of infection under the influence of cytokines (Tsay and Zouali, 2018). |
T348 |
5798-5906 |
Sentence |
denotes |
MAIT cells reside in the mucosal lining, such as in the lungs where they serve an immunoregulatory function. |
T349 |
5907-6049 |
Sentence |
denotes |
Both these cell types play an essential role in the early clearance of the SARS-CoV-2, along with other T cell subsets (Grifoni et al., 2020). |
T350 |
6050-6160 |
Sentence |
denotes |
Strategies to enhance their function are proposed to enhance the virial clearance during COVID-19 (Cao, 2020). |
T351 |
6161-6331 |
Sentence |
denotes |
Role of these cells will be further discussed under the dysfunctional immune response in section “T and B Cell Response in Mild/Moderate and Recovered COVID-19 Patients.” |
T352 |
6333-6348 |
Sentence |
denotes |
B Cell Response |
T353 |
6349-6437 |
Sentence |
denotes |
B cells, along with T cells, form the central adaptive response during viral infections. |
T354 |
6438-6568 |
Sentence |
denotes |
B cell response is highly specific, mounted by the virus-specific antibodies and other effector cytokines secreted by these cells. |
T355 |
6569-6750 |
Sentence |
denotes |
B cell activation can be follicular helper T (TFH) cell-dependent, or in some instances, independent of helper cells; both instances are prevalent in COVID-19 (Mathew et al., 2020). |
T356 |
6751-7034 |
Sentence |
denotes |
Under the influence of antigen-presenting dendritic cells, naïve CD4+ T cells differentiate into TFH cells, which are marked by high expressions of CXCR5 and IL-21, and low expressions of CCR7, IFN-γ, IL-4, and IL-17 (Rasheed et al., 2006; Nurieva et al., 2008; Morita et al., 2011). |
T357 |
7035-7228 |
Sentence |
denotes |
The activated TFH cells interact with B cells via CD40R-CD40L and other associated receptors to induce the production of antigen-specific antibodies in a well-coordinated and regulated process. |
T358 |
7229-7457 |
Sentence |
denotes |
This CD40R-CD40L interaction along with the secretion of IL-21 also allows the formation of long-lived memory B cells, while B cell-derived IL-6 and IL-27 help in reciprocal maintenance of TFH cells (Nurieva et al., 2008, 2009). |
T359 |
7458-7622 |
Sentence |
denotes |
A previous animal study has shown the essential role of these helper cells in mounting an adequate antibody response against SARS-CoV infection (Chen et al., 2010). |
T360 |
7623-7731 |
Sentence |
denotes |
The depletion of these cells was associated with a decline in antibody response and reduced viral clearance. |
T361 |
7732-7850 |
Sentence |
denotes |
Thus, virus-specific antibodies produced by B cells are critical for an effective immune response mounted by the host. |
T362 |
7851-8055 |
Sentence |
denotes |
These antibodies facilitate the clearance of the virus by either directly activating phagocytosis, opsonization, or activation of the antibody-dependent cellular cytotoxicity (ADCC) via effector NK cells. |
T363 |
8056-8167 |
Sentence |
denotes |
Cytokines released by the activation of innate and adaptive immune systems also activate the complement system. |
T364 |
8168-8317 |
Sentence |
denotes |
Viruses coated with the secreted antibodies from plasma cells eventually get eliminated by the complement system, reviewed by Risitano et al. (2020). |
T365 |
8319-8389 |
Sentence |
denotes |
T and B Cell Response in Mild/Moderate and Recovered COVID-19 Patients |
T366 |
8390-8535 |
Sentence |
denotes |
T cell response is an emerging critical determinant in keeping the SARS-CoV-2 infection under check (Huang C. et al., 2020; Liu J. et al., 2020). |
T367 |
8536-8907 |
Sentence |
denotes |
Across studies, a decline in the number of these cells positively correlates with poor clinical outcome and immuno-pathogenesis, whereas adequate T cell number and proper effector function are prevalent in patients who develop mild disease symptoms or those who successfully recovered (Chen G. et al., 2020; Li H. et al., 2020; Sekine et al., 2020; Tan L. et al., 2020b). |
T368 |
8908-9175 |
Sentence |
denotes |
Following a single patient (47-year-old woman) throughout the disease, Thevarajan et al. (2020) showed a concomitant increase in CD4+, CD8+, TFH cells, and antibody-secreting B cells from day seven after infection, which persisted for a week as the symptoms resolved. |
T369 |
9176-9381 |
Sentence |
denotes |
Other studies revealed a similar trend of revival in T cell response in patients who have successfully cleared the virus (Anft et al., 2020; Braun et al., 2020; Chen X. et al., 2020; Chen N. et al., 2020). |
T370 |
9382-9511 |
Sentence |
denotes |
SARS-CoV-2 specific reactive CD4+ and CD8+ T cells were found in 100 and 80% patients who needed mechanical ventilation (n = 10). |
T371 |
9512-9600 |
Sentence |
denotes |
PBMCs derived from these patients showed reactivity against the S protein of SARS-CoV-2. |
T372 |
9601-9796 |
Sentence |
denotes |
Further, in vitro stimulation of CD4+ T cells led to their differentiation into TH1, TH2, and TH17 subsets, as revealed by the expression of their corresponding cytokines (Weiskopf et al., 2020). |
T373 |
9797-9881 |
Sentence |
denotes |
Interestingly, 20% of non-infected healthy controls also displayed reactive T cells. |
T374 |
9882-10033 |
Sentence |
denotes |
The main limitation with this study was that the T response was studied only in critically ill patients and the small sample size was small to provide. |
T375 |
10034-10211 |
Sentence |
denotes |
By studying a cohort of 18 COVID-19 patients and 64 healthy donors, Braun et al. (2020) found reactive CD4+ (83%) cells in blood-derived from the convalescing COVID-19 patients. |
T376 |
10212-10281 |
Sentence |
denotes |
These reactive T cells were found specifically against the S protein. |
T377 |
10282-10475 |
Sentence |
denotes |
Interestingly about 35% of SARS-CoV-2 seronegative healthy donors also showed the presence of S protein reactive CD4+ T cells indicating previous exposure to the related coronavirus infections. |
T378 |
10476-10630 |
Sentence |
denotes |
Simultaneously, another study has found SARS-CoV-2 specific CD4+ T (100%) and CD8+ T (70%) cells in convalescent patients (n = 20) (Grifoni et al., 2020). |
T379 |
10631-10836 |
Sentence |
denotes |
In addition to being majorly reactive against S protein, the study found additional targets of these T cells in the form of M, N, and ORF8 proteins and other non-structural proteins like NSP3, NSP4, ORF3a. |
T380 |
10837-11064 |
Sentence |
denotes |
Further, in line with the study by Braun et al. (2020), T cells were found reactive against 40–60% of the SARS-CoV-2 uninfected patients, suggesting the presence of these reactive cells in response to previous viral infections. |
T381 |
11065-11241 |
Sentence |
denotes |
In a yet to be a peer-reviewed article, Schulien et al. (2020) has extensively studied the SARS-CoV-2 epitope-specific role of CD8+ T cells in COVID-19 (Schulien et al., 2020). |
T382 |
11242-11425 |
Sentence |
denotes |
The study found the presence of newly generated and pre-existing SARS-CoV-2 specific cells with the positive response seen in 88.4% of patients who had mild disease symptoms (n = 26). |
T383 |
11426-11494 |
Sentence |
denotes |
The most substantial response was found against N protein and ORF3a. |
T384 |
11495-11595 |
Sentence |
denotes |
Further, CD8+ T cells response was shown persistent even in the individuals who became seronegative. |
T385 |
11596-11703 |
Sentence |
denotes |
In a patient studied longitudinally (70 days), CD8+ T cell response prolonged but antibody did not persist. |
T386 |
11704-11956 |
Sentence |
denotes |
All these three studies taken together point toward the presence of functional and long-lasting reactive T cells in convalescent individuals, while others also suggest the presence of reactive T cells in critically ill patients (Weiskopf et al., 2020). |
T387 |
11957-12133 |
Sentence |
denotes |
Thus, based on these studies, it appears that COVID-19 patients who exhibit mild disease symptoms and successfully recover, display functional and long-lasting T cell response. |
T388 |
12134-12324 |
Sentence |
denotes |
However, these findings may not be definitive to provide a coherent functional view of these cells during recovery, as none of these studies compared the T cell response to disease severity. |
T389 |
12325-12412 |
Sentence |
denotes |
A further difference in the time of sample collection may also complicate the findings. |
T390 |
12413-12603 |
Sentence |
denotes |
In the study by Grifoni et al. (2020) samples were collected throughout 20–35 days after symptom onset, whereas Weiskopf et al. (2020), used samples collected after 14 days of ICU admission. |
T391 |
12604-12694 |
Sentence |
denotes |
Thus, more studies under controlled clinical settings and large cohort size are warranted. |
T392 |
12695-12858 |
Sentence |
denotes |
While addressing some of these concerns, a recent study explored T cell response in convalescent COVID-19 patients concerning disease severity (Peng et al., 2020). |
T393 |
12859-13041 |
Sentence |
denotes |
The study found robust CD4+ and CD8+ memory T cell response in severe cases (n = 14) than mild (n = 28), suggesting long-lasting memory of these cells to keep the infection in check. |
T394 |
13042-13093 |
Sentence |
denotes |
The limitation again here is the small sample size. |
T395 |
13094-13240 |
Sentence |
denotes |
Therefore, more such studies with large sample size are needed to fully understand the impact of T cell response and its long-term sustainability. |
T396 |
13241-13399 |
Sentence |
denotes |
B cell response has a temporal dynamic to human infecting CoVs, with a median time of detection for SARS-CoV as 14 days, reviewed by Huang A.T. et al. (2020). |
T397 |
13400-13657 |
Sentence |
denotes |
The peak antibody titer for IgG and IgM, and detection time of neutralizing antibody varied across studies with a lower time point of seroconversion for IgG, IgM, and IgA as 15 days (Hsueh et al., 2004; Mo et al., 2006; Cao et al., 2007; Yang et al., 2009). |
T398 |
13658-13745 |
Sentence |
denotes |
A more dynamic range of seroconversion was observed in sera from the COVID-19 patients. |
T399 |
13746-13927 |
Sentence |
denotes |
A study by Liu X. et al. (2020) on 32 patients with varying disease severity has shown detectable IgM antibodies from day four and peaked at day 20, since the onset of the symptoms. |
T400 |
13928-14004 |
Sentence |
denotes |
At the same time, IgG antibodies appeared after day 7 with a peak on day 25. |
T401 |
14005-14125 |
Sentence |
denotes |
When compared to the disease severity, mild cases had peak IgM response earlier than in severe cases (day 17 vs day 21). |
T402 |
14126-14258 |
Sentence |
denotes |
Further, severe cases exhibited more robust IgG antibody response than mild cases, as will be discussed in the subsequent section C. |
T403 |
14259-14536 |
Sentence |
denotes |
In terms of the antibody response seen after symptom onset, a similar trend was shown by Liu X. et al. (2020) who detected IgM antibodies in SARS-CoV-2 infected patients between 3 and 6 days and IgG antibodies after day 8 of symptom onset, irrespective of the disease severity. |
T404 |
14537-14670 |
Sentence |
denotes |
A study by Zhou P. et al. (2020) also found mean times of IgM, IgG, and neutralizing antibodies at 12, 14, and 11 days, respectively. |
T405 |
14671-14808 |
Sentence |
denotes |
These reports were consistent with the reports from Wu et al. (2020) in which neutralizing antibodies were detected starting from day 10. |
T406 |
14809-15009 |
Sentence |
denotes |
An elaborate antibody profile of 285 COVID-19 patients revealed 100% IgG and 94.1% IgM antibody response with a peak around the 3rd and 4th week after symptom onset, respectively (Long et al., 2020a). |
T407 |
15010-15294 |
Sentence |
denotes |
Thus, for a successful viral clearance, an adequate adaptive immune response is generated around 2nd week after symptom onset and peaks around the 3rd week for IgM and at the beginning of 4th week for IgG (Ni et al., 2020; Thevarajan et al., 2020; Wu et al., 2020; Zhao et al., 2020). |
T408 |
15295-15599 |
Sentence |
denotes |
Based on these and several other studies, it is evident that the antibody response is very dynamic in COVID-19 which may be dependent on the age, sex, genetic factors, underlying disease condition and most importantly, the type of assay used for serological testing (Guan et al., 2020; Hou et al., 2020). |
T409 |
15600-15855 |
Sentence |
denotes |
Overall, these initial reports unequivocally suggest an integral role of the regulated adaptive immune response in the early clearance of virus and thereby attenuation of the disease condition in almost 80% of the patients who show mild/moderate symptoms. |
T410 |
15856-16042 |
Sentence |
denotes |
On the other hand, in the rest, 20% severe and critically ill patients, disease symptoms positively correlate with the degree of lymphocytopenia, as will be discussed later in section C. |
T411 |
16043-16144 |
Sentence |
denotes |
A schematic representation of the functional immune response during COVID-19 is depicted in Figure 3. |
T412 |
16145-16223 |
Sentence |
denotes |
FIGURE 3 Clearance of virus infected cells by engaging adaptive immune cells. |
T413 |
16224-16334 |
Sentence |
denotes |
Virus infected ATII cells activate the neighboring lung resident AMs by minimizing the CD200-200L interaction. |
T414 |
16335-16444 |
Sentence |
denotes |
Additional requisite activation signals are provided by DAMPs, viral derived PAMPs, and cytokines like IFN-γ. |
T415 |
16445-16738 |
Sentence |
denotes |
Activated AMs along with infected ATII derived molecules activate and recruit other innate immune cells, like circulating monocytes, dendritic cells, NK cells, and neutrophils which act in a coordinated manner to eventually recruit the adaptive effector immune cells like CTLs and CD4+T cells. |
T416 |
16739-16875 |
Sentence |
denotes |
These adaptive immune cells then specifically eliminate virus infected cells while minimizing the damage to the nearby uninfected cells. |
T417 |
16876-17059 |
Sentence |
denotes |
Thus, a well-coordinated and regulated adaptive immune response with help from innate immune cells is critical for initial antiviral response to limit the further spread of the virus. |
T418 |
17060-17254 |
Sentence |
denotes |
Green arrows indicate the cytokines released by the respective activated immune cells which activate other immune cells as well as mount an antiviral response by acting on lung epithelial cells. |
T419 |
17255-17434 |
Sentence |
denotes |
An immunological enigma still eluding researchers worldwide is how the majority of COVID-19 patients remain asymptomatic, and even some with high viral load (Lee S. et al., 2020). |
T420 |
17435-17559 |
Sentence |
denotes |
This dilemma can be partly explained based on the effective functional early immune response generated by the T and B cells. |
T421 |
17560-17702 |
Sentence |
denotes |
Mathew et al. (2020) used a multidimensional immunoprobing study and functionally characterized clinical features with immunological features. |
T422 |
17703-17787 |
Sentence |
denotes |
This study defined three immunotypes based on 50 clinical and 200 immune parameters. |
T423 |
17788-18021 |
Sentence |
denotes |
The immunotype 1 was positively associated with disease severity and had hyperactivated CD4+ and CD8+ T cells, with concomitant expression of exhaustion markers, indicating robust activation followed by the exhaustion of these cells. |
T424 |
18022-18287 |
Sentence |
denotes |
This immunotype may thus be vulnerable to cytokine storm, as discussed later in section “Cytokine Storm in COVID-19 Patients.” Immunotype 2 was associated with the presence of proliferating memory B cells with the optimal activation status of CD4+ and CD8+ T cells. |
T425 |
18288-18344 |
Sentence |
denotes |
This immunotype did not associate with disease severity. |
T426 |
18345-18481 |
Sentence |
denotes |
The immunotype 3 had no activation status of CD4+ and CD8+ T cells, and thus exhibited an inverse correlation with the disease severity. |
T427 |
18482-18665 |
Sentence |
denotes |
Overall, this study addressed some of the above questions that suggested that the presence of a regulated and functional adaptive immune response is key to preventing immunopathology. |
T428 |
18666-18804 |
Sentence |
denotes |
In a similar study, the activation status of T cells associated with disease severity (acute, moderate, and severe) (Sekine et al., 2020). |
T429 |
18805-18929 |
Sentence |
denotes |
The activation status of these T cells correlated with the presence of SARS-CoV-2 specific IgG antibodies in these patients. |
T430 |
18930-19218 |
Sentence |
denotes |
Interestingly, T cells derived from convalescent mild and asymptomatic patients exhibited functional status when stimulated in vitro with SARS-CoV-2 specific antigens, suggesting the presence of well-regulated and functional T cell response in mild and asymptomatic convalescent patients. |
T431 |
19219-19421 |
Sentence |
denotes |
Thus, in patients with high viral load, an immunopathological state can be prevented if the adequate and regulated adaptive immune response is present in association with the proper interferon response. |
T432 |
19422-19709 |
Sentence |
denotes |
While in patients with compromised immune response, like in comorbid conditions, even a low viral load is sufficient to induce immunopathological changes, due to either ineffective immune response or uncontrolled hyper-activated response, as will be discussed in the subsequent sections. |
T433 |
19711-19749 |
Sentence |
denotes |
Dysfunctional Adaptive Immune Response |
T434 |
19750-19824 |
Sentence |
denotes |
A subset of COVID-19 patients displays robust activation of T and B cells. |
T435 |
19825-19990 |
Sentence |
denotes |
These exaggerated T cell responses are specifically present in patients who manifest severe disease conditions and need mechanical ventilation (Herold et al., 2020). |
T436 |
19991-20225 |
Sentence |
denotes |
Further, analysis of peripheral blood, BALF, and post-mortem lung samples of deceased patients reveal robust activation of T and B cells with a concomitant decline in the number of these cells (Kaneko et al., 2020; Liao et al., 2020). |
T437 |
20226-20408 |
Sentence |
denotes |
Thus, it is becoming apparent that a subset of COVID-19 patients displays activated adaptive immune response, which augments hyper-inflammation, thereby leading to disease worsening. |
T438 |
20409-20659 |
Sentence |
denotes |
In the subsequent section, we will specifically discuss the intricate role of T and B cells concerning their contribution to the development of the immunopathological state and how this critical antiviral immune response becomes awry during COVID-19. |
T439 |
20661-20722 |
Sentence |
denotes |
Proinflammatory Cytokines Secreted by T Cells During COVID-19 |
T440 |
20723-20886 |
Sentence |
denotes |
Hyperinflammatory condition mediated by cytokines, chemokines and associated proinflammatory molecules which are secreted by both innate and adaptive immune cells. |
T441 |
20887-21073 |
Sentence |
denotes |
However, during COVID-19, the relative contribution of adaptive immune cells towards proinflammatory molecules is still emerging, while the published studies suggest a complex interplay. |
T442 |
21074-21279 |
Sentence |
denotes |
Profiling of 21 cytokines and chemokines in 39 patients and 24 healthy controls revealed increased levels of TH1 specific cytokines like IFN-γ, IL-2, and IL-12, and TH17 specific IL-17 in peripheral blood. |
T443 |
21280-21410 |
Sentence |
denotes |
In comparison to the mild cases (n = 19), patients with severe disease (n = 10) condition had increased levels of these cytokines. |
T444 |
21411-21530 |
Sentence |
denotes |
The limitation of this study was that the median age of severe cases was higher than in mild cases (Song et al., 2020). |
T445 |
21531-21714 |
Sentence |
denotes |
Similarly, Zhou et al. (2020b) reported hyperactivated TH1 cell response with increased secretion of IFN-γ, GM-CSF, and IL-6 and with more robust expression in ICU cases than non-ICU. |
T446 |
21715-22015 |
Sentence |
denotes |
Considering the age, gender and other associated factors, a large number of other studies have now confirmed that COVID-19 patients have increased levels of TH1 specific cytokines, with more robust levels seen in severe than mild cases (Huang C. et al., 2020; Xu Z. et al., 2020; Zhou et al., 2020b). |
T447 |
22016-22157 |
Sentence |
denotes |
Similarly, CD8+ T cell-specific cytokines increased in COVID-19 patients, more pronounced in severe than mild condition (Zhou et al., 2020b). |
T448 |
22158-22305 |
Sentence |
denotes |
Increased expression of GM-CSF was found in CD8+ T cells from ICU patients than non-ICU, while no difference was observed in IL-6 and TNF-α levels. |
T449 |
22306-22603 |
Sentence |
denotes |
PBMCs derived from COVID-19 patients and stimulated in vitro showed an increase in expression of CCL2, CXCL10, Eotaxin, and IL-1RA, and stimulation of CD8+ T cells were associated with an increase in IFN-γ levels, which indicates the functional responsiveness of these cells (Mathew et al., 2020). |
T450 |
22604-22705 |
Sentence |
denotes |
These studies thus suggest a robust activation of TH1 specific and CD8+ T cells in COVID-19 patients. |
T451 |
22706-22818 |
Sentence |
denotes |
On the contrary, there are studies which show decreased cytokine expression by T cells in severe COVID-19 cases. |
T452 |
22819-22949 |
Sentence |
denotes |
A study by Zheng H.Y. et al. (2020) showed a lower expression of IFN-γ, IL-2, and TNF-α in CD4+ T cells derived from severe cases. |
T453 |
22950-23046 |
Sentence |
denotes |
Similarly, a decrease in IL-2+ CD8+ and IFN-γ+ CD8+ cells was also observed (Diao et al., 2020). |
T454 |
23047-23338 |
Sentence |
denotes |
Although most studies point toward the robust activation and release of proinflammatory cytokines by CD4+ and CD8+ T cells, the discrepancy in latter studies could attribute to the functional exhaustion of these cells, which will we will discuss in section “Lymphocytopenia During COVID-19.” |
T455 |
23339-23568 |
Sentence |
denotes |
Besides the presence of TH1 cytokines, TH2 cytokines like IL-4 and IL-5 and TH17 specific IL-17 were reported in some studies (Han et al., 2020; Huang C. et al., 2020; Song et al., 2020; Tan L. et al., 2020b; Xu Z. et al., 2020). |
T456 |
23569-23743 |
Sentence |
denotes |
The presence of TH2 cytokines usually seen in mild cases may be accounted for by the presence of other respiratory conditions with TH2 specific response (Laing et al., 2020). |
T457 |
23744-24074 |
Sentence |
denotes |
Overall, all these studies point toward the increased secretion of proinflammatory molecules by T lymphocytes in COVID-19, albeit with a heterogeneous response, which may be due to the variation in the age of the patients studied, different sampling times and presence of the comorbid condition, which needs further investigation. |
T458 |
24076-24145 |
Sentence |
denotes |
Activation and Exhaustion Status of T Cells During COVID-19 Infection |
T459 |
24146-24281 |
Sentence |
denotes |
The activation, exhaustion, and proliferation response of T and B cells are considered an integral determinant of the disease severity. |
T460 |
24282-24553 |
Sentence |
denotes |
Unequivocally, studies have shown lymphocytopenia as a predictive marker which may also determine the disease severity in COVID-19 patients (Liu J. et al., 2020; Tan L. et al., 2020b; Wang et al., 2020b; Yang A.P. et al., 2020; Yang X. et al., 2020; Zhang et al., 2020a). |
T461 |
24554-24669 |
Sentence |
denotes |
However, contradictory reports exist regarding the functional and exhaustion status of these cells during COVID-19. |
T462 |
24670-24878 |
Sentence |
denotes |
Further, understanding these changes throughout the disease has remained a challenge, considering the complexity in the underlying immune response, comorbid condition, and previous exposure to the infections. |
T463 |
24879-25038 |
Sentence |
denotes |
Peripheral blood study of a single patient (50-year male) revealed robust activation of CD4+ and CD8+ T cells marked by HLA-DR expression (Xu Z. et al., 2020). |
T464 |
25039-25126 |
Sentence |
denotes |
However, the major limitation of this study was that only a single patient was studied. |
T465 |
25127-25265 |
Sentence |
denotes |
Using multiparameter flow cytometry approach Kuri-Cervantes et al. (2020) studied 35 COVID-19 patients (n = 7 moderate and n = 28 severe). |
T466 |
25266-25445 |
Sentence |
denotes |
The study revealed that a subset of severe cases displayed T cell activation as revealed by CD38 and HLA-DR expression in both CD4+ and CD8+ T cells (Kuri-Cervantes et al., 2020). |
T467 |
25446-25640 |
Sentence |
denotes |
By analyzing, PBMCs derived from healthy (n = 5) and severe cases (n = 16), the authors found an increase in the percentage of cytotoxic CD8+ memory cells as revealed by perforin and granzyme B. |
T468 |
25641-25756 |
Sentence |
denotes |
Similarly, a subset of severe cases had increased Ki-67 expressing CD4+ and CD8+ T cells, displaying proliferation. |
T469 |
25757-25949 |
Sentence |
denotes |
At the same time, these findings revealed heterogeneous T cell response but overall suggested a skew towards the activation and proliferation status of these cells in a subset of severe cases. |
T470 |
25950-26119 |
Sentence |
denotes |
The limitation of this finding is again the small sample size which may be the reason for the inconclusive findings of the T cell status concerning the disease severity. |
T471 |
26120-26278 |
Sentence |
denotes |
Similar multiparameter flow cytometry approach was used by De Biasi et al. (2020) to study T cell response in healthy (n = 12) and COVID-19 patients (n = 21). |
T472 |
26279-26389 |
Sentence |
denotes |
The study found activated status of CD4+ and CD8+ T cells as revealed by an increase in CD38+HLA-D population. |
T473 |
26390-26532 |
Sentence |
denotes |
Activated status of the CD4+ T and CD8+ T cells was further confirmed by production of IFN-γ, TNF-α, IL-17, and IL-2 when stimulated in vitro. |
T474 |
26533-26711 |
Sentence |
denotes |
The major limitation of this study was that the sample size was small, which restricted the comparison between the T cell responses across patients with various disease severity. |
T475 |
26712-26854 |
Sentence |
denotes |
In another study, Song et al. (2020) showed the activated status of CD8+ T but not CD4+ T cells in severe (n = 9) than mild (n = 20) patients. |
T476 |
26855-27011 |
Sentence |
denotes |
The activated status of CD8+ T cells reflected by the increased population of CD38+HLA-DR+, HLA-DR+, and CD38+HLA-DR+ marker expression (Song et al., 2020). |
T477 |
27012-27177 |
Sentence |
denotes |
Further, CD8+ T cells were associated with increased cytolytic markers like granzyme B, perforin, and granulysin with more pronounced activation in severe than mild. |
T478 |
27178-27305 |
Sentence |
denotes |
While across studies, it has become apparent that T cells show robust activation status in severe cases than mild and moderate. |
T479 |
27306-27409 |
Sentence |
denotes |
These cells also exhibit exhaustion status, which may occur concomitantly with their activation status. |
T480 |
27410-27633 |
Sentence |
denotes |
Deep immune profiling of 125 patients by Mathew et al. (2020) demonstrated that both CD4+ and CD8+ T cells exhibit activation status as revealed by coexpression of CD38 and HLA-DR which corresponded to the disease severity. |
T481 |
27634-27759 |
Sentence |
denotes |
Further, these cells were also associated with concomitant expression of proliferation (Ki-67) and exhaustion (PD-1) markers. |
T482 |
27760-27958 |
Sentence |
denotes |
This study thus suggests that hyperactivated status of T cells may eventually lead to their exhaustion, and thus these functional and exhaustion features of T cells may reflect the disease severity. |
T483 |
27959-28113 |
Sentence |
denotes |
A study by Zheng M. et al. (2020) in a cohort of 68 COVID-19 patients revealed extensive CD8+ T cell exhaustion as shown by increased expression of NKG2A. |
T484 |
28114-28341 |
Sentence |
denotes |
Intracellular cytokine staining (IFN-γ, IL-2, and granzyme B) further confirmed a decrease in the activation profile of these cells, which was more pronounced in severe (n = 55) than mild (n = 13) cases (Zheng M. et al., 2020). |
T485 |
28342-28581 |
Sentence |
denotes |
As mentioned earlier in the study by Song et al. (2020) and De Biasi et al. (2020) T cells showed activation status that was also concomitantly seen with express of exhaustion markers PD-1 and TIM-3 on CD8+ T cells and TIM-3 on CD4+ cells. |
T486 |
28582-28660 |
Sentence |
denotes |
The exhaustion was more pronounced in severe cases (n = 9) than mild (n = 20). |
T487 |
28661-28766 |
Sentence |
denotes |
However, both these studies did not consider the age of the patients when comparing the disease severity. |
T488 |
28767-28884 |
Sentence |
denotes |
Further, the study did not consider the temporal dynamics of these cells while measuring their functional properties. |
T489 |
28885-29096 |
Sentence |
denotes |
In agreement, Zheng H.Y. et al. (2020) showed reduced functional activation of CD4+ T cells in severe (n = 6) than mild (n = 10) group as revealed by a lower proportion of IFN-γ and IL-2 expressing CD4+ T cells. |
T490 |
29097-29196 |
Sentence |
denotes |
While IL-2 expressing CD4+ T cell population was also significantly lower in healthy vs mild group. |
T491 |
29197-29377 |
Sentence |
denotes |
Further, CD8+ T cells displayed exhaustion as revealed by an increase in CTLA-4 in severe cases than mild and TGIT in severe than healthy, while PD-1 was more in mild than healthy. |
T492 |
29378-29490 |
Sentence |
denotes |
Exhaustive states of both CD4+ and CD8+ T cells were also present in patients requiring ICU (Diao et al., 2020). |
T493 |
29491-29622 |
Sentence |
denotes |
The exhaustive state was apparent by an increase in PD-1 and Tim-3 expression, which was more pronounced in CD8+ than CD4+ T cells. |
T494 |
29623-29965 |
Sentence |
denotes |
These studies along with others thus suggest that robust activation followed by the exhaustion of CD4+ and CD8+ T cells may be responsible for the disease progression, while therapies like checkpoint inhibitors (anti-PD-1 antibody; NCT04268537) which may prevent T cell exhaustion and restore their functional state may benefit some patients. |
T495 |
29966-30064 |
Sentence |
denotes |
More studies are necessary before using such an approach can be used for therapeutic intervention. |
T496 |
30065-30184 |
Sentence |
denotes |
A post-mortem study of deceased COVID-19 patients conducted to find the status of these cells at the site of infection. |
T497 |
30185-30354 |
Sentence |
denotes |
T cell profiling and their activation status in the lungs revealed an increase in the presence of CD4+ and CD8+ T cells exhibiting activation status (Song et al., 2020). |
T498 |
30355-30468 |
Sentence |
denotes |
This increase in infiltration of these cells was concomitantly associated with their decline in peripheral blood. |
T499 |
30469-30582 |
Sentence |
denotes |
Others presented a similar activation profile of CD8+ T cells (Kuri-Cervantes et al., 2020; Mathew et al., 2020). |
T500 |
30583-30928 |
Sentence |
denotes |
This activated state of CD8+ T cells was consistently present across studies, with reports of immune profiling in BALF samples from COVID-19 patients, which showed increased CD4+ and CD8+ T cells in the lungs in both mild and severe cases along with the increased expression of CD8+ T cell cytolytic genes like GZMA and GZMK (Liao et al., 2020). |
T501 |
30929-31127 |
Sentence |
denotes |
Thus, these studies point towards heterogeneous activation and exhaustion status of T cells in peripheral blood, while a more consistent activated status at the site of infection (lungs) (Figure 4). |
T502 |
31128-31290 |
Sentence |
denotes |
FIGURE 4 T and B cell immune response during SARS-CoV-2 infection. (A) The activation status of CD4+ and CD8+ T in the circulation is indicated by CD38+ HLA-DR+. |
T503 |
31291-31428 |
Sentence |
denotes |
These activated T cells are further recruited at the sites of infection (initially lungs) in the presence of their respective chemokines. |
T504 |
31429-31646 |
Sentence |
denotes |
The activated CD4+ T cells are marked by the presence of cytokines like IFN-γ, IL-2, IL-12, IL-6, and GM-CSF, whereas activated CD8+T (cytotoxic T cells) are marked by the secretion of granzymes, perforins, and IFN-γ. |
T505 |
31647-31975 |
Sentence |
denotes |
During SARS-CoV-2 infection, activated CD8+T cells exhibiting increased expression of granzyme A, B, and K (GZM-B, GZM-A, and GZM-K) were found in the lungs (Liao et al., 2020; Song et al., 2020; Zheng M. et al., 2020). (B) T cells were also found to exhibit exhausted state as marked by the expression of PD-1, Tim3, and NKG2A. |
T506 |
31976-32242 |
Sentence |
denotes |
However, most studies showing exhausted T cells were confined to the peripheral blood, while lungs were mostly shown to have activated T cells but with concomitant expression of some exhaustive markers, suggesting that the activation state is followed by exhaustion. |
T507 |
32243-32615 |
Sentence |
denotes |
The exhaustive T cells are marked by the reduced expression of respective chemokines and cytolytic granules. (C) Similarly, antibody-producing B cells (plasmablasts; PB) were shown to exhibit activation status as reflected by the expression of IL4R, TNFSF13B, and XBP1, while at the same time, the exhausted status of these cells was also reported in the peripheral blood. |
T508 |
32616-32694 |
Sentence |
denotes |
Exhaustive state of B cells is reflected by a decrease in antibody production. |
T509 |
32695-32884 |
Sentence |
denotes |
Further, it appears that unlike CD4+ T cells, the activation status of CD8+ T cells is more pronounced, which may account for their relatively faster exhaustion state (Wherry et al., 2007). |
T510 |
32885-33093 |
Sentence |
denotes |
Interestingly, by studying the CD8+T cell response in convalescent patients, Habel et al. (2020) found that these cells skewed toward naïve, stem cell and central memory phenotypes, with low effector T cells. |
T511 |
33094-33210 |
Sentence |
denotes |
While comparing the response with Influenza A viruses, SARS-CoV-2 directed CD8+ T exhibit relatively lower response. |
T512 |
33211-33553 |
Sentence |
denotes |
Others have also shown a significant decline in CD8+ T cell subsets (naïve, effector, and memory) in COVID-19 patients, with a more pronounced decline in critical (n = 3) than severe (n = 5), and mild (n = 4), suggesting their robust activation during early disease followed by exhaustion during the critical condition (Wang W. et al., 2020). |
T513 |
33554-33674 |
Sentence |
denotes |
On the contrary, CD4+ T cells were higher in the mild and critical cases than severe cases and healthy control (n = 12). |
T514 |
33675-33904 |
Sentence |
denotes |
These results imply that the overall T cell response is heterogenous, while CD8+ response, though robust during infection and correlates with the disease severity; but the response may not be long-lasting, at least in some cases. |
T515 |
33905-33986 |
Sentence |
denotes |
Both CD4+ and CD8+ T cells also exhibit dysregulated response (Qin et al., 2020). |
T516 |
33987-34105 |
Sentence |
denotes |
Decreased levels of CD4+ regulatory cells as marked by CD3+ CD4+ CD25+ CD127low+ population was found in severe cases. |
T517 |
34106-34203 |
Sentence |
denotes |
Similarly, the study found decreased CD8+ suppressor T cells (CD3+, CD8+, CD28+) in severe cases. |
T518 |
34204-34432 |
Sentence |
denotes |
Overall, more comprehensive studies are warranted with larger cohort size, to profile local vs systemic T cell response and persistence simultaneously, and correlate these responses with disease severity in age-matched patients. |
T519 |
34434-34474 |
Sentence |
denotes |
Impaired B Cell Response During COVID-19 |
T520 |
34475-34599 |
Sentence |
denotes |
Regulated and controlled B cell response is critical for the effective immune response against the CoVs, as discussed above. |
T521 |
34600-34717 |
Sentence |
denotes |
However, under certain conditions, B cell response may be detrimental and aggravate the underlying disease condition. |
T522 |
34718-34905 |
Sentence |
denotes |
A notion has emerged, which suggests that in COVID-19 patients, B cell number though reduced, but these cells display robust activation in some cases that correlate with disease severity. |
T523 |
34906-35091 |
Sentence |
denotes |
Deep immune profiling integrated with computational approach revealed intricate relations of B cell response with clinical parameters at various stages of the COVID-19 disease severity. |
T524 |
35092-35204 |
Sentence |
denotes |
These cells express proliferation (Ki67+), differentiation (CD27+ CD38+), as well as exhaustion markers (PD-1+). |
T525 |
35205-35372 |
Sentence |
denotes |
More robust expression of these markers was observed in severe cases compared to mild-moderate, with an overall decrease in memory B cell number (Mathew et al., 2020). |
T526 |
35373-35527 |
Sentence |
denotes |
Further, 70% of the patients reported have IgG and IgM S protein-specific antibodies, suggesting activation status of the antibody-secreting plasmablasts. |
T527 |
35528-35699 |
Sentence |
denotes |
Thus, this study shows that B cells, in severe cases, display concomitant activation and exhaustion markers, while mild cases or healthy controls showed a normal response. |
T528 |
35700-35796 |
Sentence |
denotes |
However, how this activated status of B cells had an impact on disease severity was not studied. |
T529 |
35797-36017 |
Sentence |
denotes |
By looking at the alleged relationship of activated B cells with disease severity, Woodruff et al. (2020) showed robust activation status of extrafollicular B cells which resembled their behavior in autoimmune condition. |
T530 |
36018-36259 |
Sentence |
denotes |
The activation status of these cells was found more pronounced in critically ill patients (n = 10) than non-critical (n = 7) and healthy control (n = 17), which correlated with SARS-CoV-2-specific antibody production and disease progression. |
T531 |
36260-36478 |
Sentence |
denotes |
Further, an increase in antibody-secreting cells (ASCs) was found in critically ill cases compared to non-severe cases along with an increase in S protein-specific antibodies, probably with a non-neutralizing property. |
T532 |
36479-36689 |
Sentence |
denotes |
This study shows that in some patients with a critical disease condition, robust B cell response and presence of SARS-CoV-2 antigen-specific antibodies may be associated with worsening of the disease condition. |
T533 |
36690-36777 |
Sentence |
denotes |
The ASCs were identified as the population of cells with CD138+ and CD21low expression. |
T534 |
36778-36866 |
Sentence |
denotes |
However, no comparison was drawn between various age groups concerning disease severity. |
T535 |
36867-37003 |
Sentence |
denotes |
While across studies, B cell activation is apparent in severe cases, it is subsequently associated with a sharp decline in their number. |
T536 |
37004-37144 |
Sentence |
denotes |
Various mechanisms may be responsible for this decline, among which B cell exhaustion is one, but still poorly understood (Yi et al., 2010). |
T537 |
37145-37252 |
Sentence |
denotes |
A recent study has provided mechanistic insights into how some cases of COVID-19 exhibit low B cell number. |
T538 |
37253-37481 |
Sentence |
denotes |
Kaneko et al. (2020) studied the post-mortem samples (n = 11) of thoracic lymph nodes and spleens and found that Bcl-6+ germinal center (GC) B cells highly reduced in these patients in comparison to non-COVID-19 control (n = 6). |
T539 |
37482-37630 |
Sentence |
denotes |
This decline in GC was also associated with a decrease in TFH cell differentiation and an increase in the number of TH1 cells (Kaneko et al., 2020). |
T540 |
37631-37709 |
Sentence |
denotes |
Further, an increase in expression of TNF-α levels was found in the follicles. |
T541 |
37710-37942 |
Sentence |
denotes |
Based on previous studies that TNF-α inhibits the lymphoid follicular development, and high levels of this pleiotropic cytokine is the hallmark of COVID-19, the authors attributed the reduction in GC to high levels of this cytokine. |
T542 |
37943-38116 |
Sentence |
denotes |
In addition to the study in post-mortem samples, the authors conducted B cell analysis in peripheral blood samples from COVID-19 patients at different stages of the disease. |
T543 |
38117-38413 |
Sentence |
denotes |
In line with the post-mortem data, patients with severe disease condition (n = 25) had a significant decrease in the number of naïve B cells, CD19+ B cells, and follicular B cell subsets in comparison to the healthy controls (n = 4), convalescent patients (n = 39), and moderate patients (n = 4). |
T544 |
38414-38508 |
Sentence |
denotes |
Thus, this study provides a probable cause for the B cell decline in severe cases of Covid-19. |
T545 |
38509-38680 |
Sentence |
denotes |
However, there was a significant difference in the mean age of severe patients (higher between 58 and 60) than the control, convalescent, and moderate group (30–45 years). |
T546 |
38681-38766 |
Sentence |
denotes |
Thus, the effect of age on the decline in B cells cannot be undermined in this study. |
T547 |
38767-38966 |
Sentence |
denotes |
More studies are needed to specifically look into the B cell number and activation status in COVID-19 patients concerning the disease severity to get a clear understanding of the role of these cells. |
T548 |
38968-38997 |
Sentence |
denotes |
Antibody Dynamics in COVID-19 |
T549 |
38998-39136 |
Sentence |
denotes |
Antibody-based therapy is being considered as a potential intervention for COVID-19, owing to the successful preliminary results with CPT. |
T550 |
39137-39315 |
Sentence |
denotes |
However, this treatment approach may be associated with the risk of exacerbating COVID-19 severity, based on the experience from previous viral infections (Salazar et al., 2017). |
T551 |
39316-39534 |
Sentence |
denotes |
Further, like previous SARS-CoV infections, antibody response may not always favor viral clearance, instead of contributing to the underlying immunopathology in some instances (Zhang et al., 2006; Newton et al., 2016). |
T552 |
39535-39764 |
Sentence |
denotes |
This immunopathological state may thus attribute to factors such as robust and unregulated activation of B cells, ADE, presence of cross-reactive but non-neutralizing antibodies, and failure to mount a controlled B cell response. |
T553 |
39765-39961 |
Sentence |
denotes |
Across studies, higher antibody titers detected in patients with severe and critical condition in comparison to non-severe cases (Long et al., 2020a; Gudbjartsson et al., 2020; Zhao et al., 2020). |
T554 |
39962-40227 |
Sentence |
denotes |
One can argue that higher antibody titer should be beneficial to provide an adequate antiviral response but can be countered by the finding that higher antibody titers found in a large number of severe cases and patients requiring ventilation (Kaneko et al., 2020). |
T555 |
40228-40391 |
Sentence |
denotes |
This contradiction is yet to resolve, and the emerging data suggest that higher antibody response may reflect the over-activation and uncontrolled B cell response. |
T556 |
40392-40516 |
Sentence |
denotes |
Zheng M. et al. (2020) showed the presence of RBD-specific IgG and IgA antibodies in patients with severe disease condition. |
T557 |
40517-40592 |
Sentence |
denotes |
The study included 13 severe and 41 non-severe cases of various age groups. |
T558 |
40593-40752 |
Sentence |
denotes |
Along with increased IgG and IgA levels, severe cases also had an increased number of antibody-secreting cells and TFH cells, which aid in antibody production. |
T559 |
40753-40921 |
Sentence |
denotes |
Further, a close correlation of proinflammatory cytokines and chemokines like IL-6, CXCL10 and complement activation marker C5a found with the severe disease condition. |
T560 |
40922-41049 |
Sentence |
denotes |
This study provided a direct relation of inflammatory response with humoral immune response in context to the disease severity. |
T561 |
41050-41152 |
Sentence |
denotes |
However, the antigen-neutralizing property of these SARS-CoV-2 specific antibodies was not determined. |
T562 |
41153-41336 |
Sentence |
denotes |
Further, a low sample size of severe cases was another limiting factor to provide a definitive conclusion that robust antibody response may positively correlate with disease severity. |
T563 |
41337-41469 |
Sentence |
denotes |
Similarly, Zhao et al. (2020) studied antibody response in 173 clinically diagnosed COVID-19 patients with a median age of 48 years. |
T564 |
41470-41622 |
Sentence |
denotes |
Among these, nine patients (three critical and six non-critical) studied longitudinally for the relation of antibody response with the disease severity. |
T565 |
41623-41702 |
Sentence |
denotes |
Antibody titer was higher in the critical patients as compared to non-critical. |
T566 |
41703-41916 |
Sentence |
denotes |
This higher titer of antibodies was not reflected by the clearance of the virus, thus suggesting that antibody response in critical cases may be associated with worse disease outcome rather than protective effect. |
T567 |
41917-42014 |
Sentence |
denotes |
However, like other studies, this study also suffers from the same limitation of low sample size. |
T568 |
42015-42229 |
Sentence |
denotes |
In line with the notion that antibody response is higher in severe patients, a large population study (n = 30,576 persons from Iceland) (Gudbjartsson et al., 2020) conducted in Iceland revealed similar observation. |
T569 |
42230-42418 |
Sentence |
denotes |
The study provided a comprehensive account of the relation of antibody response concerning age, sex, body-mass index, drugs habits like smoking and the use of anti-inflammatory medication. |
T570 |
42419-42587 |
Sentence |
denotes |
Results show that patients with smoking habit and who were on anti-inflammatory medication, had lower antibody levels, while body mass index had a positive association. |
T571 |
42588-42777 |
Sentence |
denotes |
The data thus suggest that antibody response may not always favor clearance of the virus, but in some instances, higher antibody levels may make the patients more vulnerable to the disease. |
T572 |
42778-42926 |
Sentence |
denotes |
This detrimental relation of antibody response with poor disease outcome was also prevalent in the previous SARS-CoV infection (Zhang et al., 2006). |
T573 |
42927-43172 |
Sentence |
denotes |
In a study on the sera samples obtained from SARS-CoV infected patients, a faster S protein-specific antibody response was found in patients who did not survive (14.7 days), as compared with the patients who recovered from the disease (20 days). |
T574 |
43173-43305 |
Sentence |
denotes |
Further, the antibody titer was significantly higher in the deceased patients with faster production than in the recovered patients. |
T575 |
43306-43497 |
Sentence |
denotes |
To mechanistically understand why antibody response has a more detrimental effect than protective, Liu et al. (2019) studied viral antibody response in animal models (Chinese rhesus monkeys). |
T576 |
43498-43667 |
Sentence |
denotes |
When animals infected with the SARS-CoV and adoptively transferred with anti-S protein IgG could not prevent the infection but instead displayed severe disease symptoms. |
T577 |
43668-43865 |
Sentence |
denotes |
Presence of the S protein antibody abrogated wound healing, induced macrophage/monocyte infiltration into the lungs and caused the release of proinflammatory cytokine followed by acute lung injury. |
T578 |
43866-44032 |
Sentence |
denotes |
This study thus demonstrated that the presence of S protein-specific antibody might have a deleterious effect in inducing lung injury, irrespective of the viral load. |
T579 |
44033-44164 |
Sentence |
denotes |
However, since mechanistic details are difficult to discern in clinical samples, more studies in animal models need to be explored. |
T580 |
44165-44454 |
Sentence |
denotes |
Further, owing to the dynamics of antibody response in clinical samples concerning underlying disease condition, age, and genetic factors; animal models will provide a cleaner system to delineate the antibody dynamics with respect to disease severity (Guan et al., 2020; Hou et al., 2020). |
T581 |
44455-44584 |
Sentence |
denotes |
Contrary to B cell activation, some studies have shown lower antibody durability in both mild and severe cases (Yu et al., 2020). |
T582 |
44585-44739 |
Sentence |
denotes |
In a longitudinal study on a 26-year-old woman with a moderate disease condition, antibody response disappeared within three months (Liu A. et al., 2020). |
T583 |
44740-44941 |
Sentence |
denotes |
In a sizable cohort of samples, asymptomatic patients (n = 37 with median age 41 years) had relatively lower durability of the IgG and IgM antibodies in comparison to the symptomatic patients (n = 37). |
T584 |
44942-45055 |
Sentence |
denotes |
Further, the viral shedding in the asymptomatic group was higher than the symptomatic group (Long et al., 2020b). |
T585 |
45056-45258 |
Sentence |
denotes |
Similarly, Ibarrondo et al. has shown the same antibody durability in 34 COVID-19 patients with a mean age of 43 years when studied longitudinally for a period of upto 4 months (Ibarrondo et al., 2020). |
T586 |
45259-45380 |
Sentence |
denotes |
The authors found a significant decline in IgG antibodies in the sera of convalescent patients with mostly mild symptoms. |
T587 |
45381-45546 |
Sentence |
denotes |
A declining trend was seen for multiple SARS-CoV-2 antibodies like IgG N, IgM, IgG S1, and IgA S1 in the longitudinal analysis (n = 487) (Gudbjartsson et al., 2020). |
T588 |
45547-45698 |
Sentence |
denotes |
In another longitudinal study, the disappearance of S and N protein-specific antibodies was observed within 3 months of recovery (Liu A. et al., 2020). |
T589 |
45699-46027 |
Sentence |
denotes |
Based on these reports, we can infer that the antibody response in some COVID-19 patients may not be long-lasting, which poses a challenge for antibody-based therapy and vaccine research—further, these data caution towards chances of reinfection, as shown to be the case with other seasonal coronaviruses (Edridge et al., 2020). |
T590 |
46028-46166 |
Sentence |
denotes |
However, larger cohort size and longer time frame longitudinal studies are needed to find the durability of antibody response in COVID-19. |
T591 |
46167-46318 |
Sentence |
denotes |
Further, a comparison of various disease states with corresponding antibody response will provide clearer insight as to how this response is regulated. |
T592 |
46319-46553 |
Sentence |
denotes |
It appears that in patients with severe disease symptoms, TNF-α may influence the GC and hence B cell number (Kaneko et al., 2020), whether the same holds for asymptomatic patients with compromised antibody durability remains elusive. |
T593 |
46554-46687 |
Sentence |
denotes |
This dynamic antibody response is critical while considering convalescent plasma therapy (CPT) for severe or critically ill patients. |
T594 |
46688-46820 |
Sentence |
denotes |
If a patient already has sufficient antibodies, CPT may not be a viable treatment option (Anderson et al., 2020; Duan et al., 2020). |
T595 |
46821-46964 |
Sentence |
denotes |
While many studies have reported success with CPT, some studies have shown no added beneficial effects with this approach (Li L. et al., 2020). |
T596 |
46965-47280 |
Sentence |
denotes |
Thus, pre-caution should be taken while using this approach, i.e., if a patient already has adequate virus-specific antibodies or presence of cross-reactive and auto-antibodies, plasma therapy may do more harm than good, which may be the reason with non-responsiveness of CPT in some patients (Nagoba et al., 2020). |
T597 |
47282-47346 |
Sentence |
denotes |
SARS-CoV-2 Antibody Cross-Reactivity and Neutralization Property |
T598 |
47347-47431 |
Sentence |
denotes |
A range of SARS-CoV specific antibodies have shown cross-reactivity with SARS-CoV-2. |
T599 |
47432-47516 |
Sentence |
denotes |
These antibodies target S protein and mostly the RBD region (Hoffmann et al., 2020). |
T600 |
47517-47665 |
Sentence |
denotes |
Monoclonal antibodies against SARS-CoV such as CR3022 and S309 have shown cross-reactivity with SARS-CoV-2 (Pinto et al., 2020; Wang et al., 2020a). |
T601 |
47666-47922 |
Sentence |
denotes |
Similarly, in a study of 285 patients, S protein-specific antibodies from SARS-CoV showed cross-reactivity with CoV-2 N protein in a subset of patients (n = 5), whereas no-cross reactivity was detected against S1 subunit of SARS-CoV-2 (Long et al., 2020a). |
T602 |
47923-48040 |
Sentence |
denotes |
Thus, the cross-reactive nature of some of these antibodies may ensure their efficacy against multiple coronaviruses. |
T603 |
48041-48183 |
Sentence |
denotes |
However, at the same time, these cross-reactive antibodies should also have neutralizing property; otherwise, they will have a harmful effect. |
T604 |
48184-48308 |
Sentence |
denotes |
A recent study explored the cross-reactive and neutralization property of these antibodies simultaneously (Lv et al., 2020). |
T605 |
48309-48515 |
Sentence |
denotes |
This study used plasma from 15 SARS-CoV-2 and 7 SARS-CoV patients and found a high degree of cross-reactivity between the antibody response from these samples, but a very low antibody neutralizing property. |
T606 |
48516-48597 |
Sentence |
denotes |
These results were further confirmed in animal models of SARS-CoV-2 and SARS-CoV. |
T607 |
48598-48776 |
Sentence |
denotes |
While S309 antibody showed better neutralization property against SARS-CoV-2, the neutralization properties for CR3022 are not yet known (Pinto et al., 2020; Wang et al., 2020a). |
T608 |
48777-48975 |
Sentence |
denotes |
Thus, although a high degree of cross-reactivity of the antibody response from SARS-CoV-2 can be found with other related CoVs, the neutralizing property of these antibodies may be epitope specific. |
T609 |
48976-49202 |
Sentence |
denotes |
The weak neutralizing property of such cross-reactive antibodies should thoroughly be tested before usage as a therapeutic intervention, to prevent the complications which may arise due to antibody-dependent enhancement (ADE). |
T610 |
49203-49285 |
Sentence |
denotes |
These factors also become essential while considering convalescent plasma therapy. |
T611 |
49286-49403 |
Sentence |
denotes |
In an elegant recent study, Cao et al. (2020) performed sc-RNA-seq of B cells from 60 convalescent COVID-19 patients. |
T612 |
49404-49528 |
Sentence |
denotes |
The study led to the identification of 14 neutralizing antibodies, among which one (BD-368-2) showed the most potent effect. |
T613 |
49529-49659 |
Sentence |
denotes |
BD-368-2 was further explored for its efficacy in animal models and showed therapeutic potential in SARS-CoV-2 transgenic animals. |
T614 |
49660-49900 |
Sentence |
denotes |
Further, the study suggested the use of two different monoclonal antibodies targeting different epitopes as a more viable therapeutic intervention than a single antibody, which is impressive considering the emerging mutations in SARS-CoV-2. |
T615 |
49901-50057 |
Sentence |
denotes |
Thus, more research in this direction is needed to find antibodies with potent neutralization property for targeted therapy to alleviate the disease burden. |
T616 |
50059-50101 |
Sentence |
denotes |
Antibody Dependent Enhancement in COVID-19 |
T617 |
50102-50212 |
Sentence |
denotes |
Non-neutralizing but cross-reactive antibodies may lead to ADE and hence enhance the immunopathological state. |
T618 |
50213-50458 |
Sentence |
denotes |
ADE can occur through various pathways, the most important among which include endocytosis of antibody conjugated virus by the phagocytic cells (via Fc gamma receptor IIa (FcγRIIa) and enhanced antibody immune complex formation (Kulkarni, 2020). |
T619 |
50459-50664 |
Sentence |
denotes |
Virus uptake by the phagocytic cells induces robust propagation and hence may further aggravate the disease condition, while antibody immune complex formation may generate a high pro-inflammatory response. |
T620 |
50665-50862 |
Sentence |
denotes |
Experience from previous viral infections has shown that ADE may lead to worse disease outcome in some patients with the presence of non-neutralizing antibodies, reviewed by Lee W.S. et al. (2020). |
T621 |
50863-50958 |
Sentence |
denotes |
In vitro studies on monocytes and macrophages have shown ADE in SARS-CoV (Flipse et al., 2016). |
T622 |
50959-51086 |
Sentence |
denotes |
However, no definitive clinical data is available that indicates the occurrence of ADE during SARS-CoV or SARS-CoV-2 infection. |
T623 |
51087-51309 |
Sentence |
denotes |
Nevertheless, based on the substantial cross-reactivity between various epitope regions of CoVs, some patients may exhibit ADE due to the presence of cross-reactive but non-neutralizing antibodies from previous infections. |
T624 |
51311-51345 |
Sentence |
denotes |
Unconventional T Cells in COVID-19 |
T625 |
51346-51500 |
Sentence |
denotes |
Bronchial alveolar lavage fluid analysis of 3 COVID-19 patients reveals a high number of NKT cells during the acute phase of infection (Kim et al., 2020). |
T626 |
51501-51576 |
Sentence |
denotes |
This increase in NKT cells was similarly reflected in the peripheral blood. |
T627 |
51577-51664 |
Sentence |
denotes |
Conversely, a decline in the number of these cells was found during the recovery phase. |
T628 |
51665-51862 |
Sentence |
denotes |
These results thus suggest a close correlation of the NKT cell activity in COVID-19 and the presence of these cells may be required for the clearance of virus during the initial phase of infection. |
T629 |
51863-52025 |
Sentence |
denotes |
Concomitantly, increased infiltration and activity of these cells may lead to a more severe outcome associated with eosinophilic pneumonia, as shown in one study. |
T630 |
52026-52154 |
Sentence |
denotes |
However, no direct correlation of these cells types with disease severity was found, probably due to meagre sample size (n = 3). |
T631 |
52155-52325 |
Sentence |
denotes |
Further, the samples used in this study were collected at different time points after the onset of symptoms, which may have complicated the interpretation of the results. |
T632 |
52326-52629 |
Sentence |
denotes |
In another study on 30 COVID-19 patients with a varied range of disease severity from mild, moderate to severe, a reduction in the total peripheral blood NKT cells was seen across groups, with no difference in the overall number between ICU (n = 10) and non-ICU patients (n = 11) (Mazzoni et al., 2020). |
T633 |
52630-52836 |
Sentence |
denotes |
Similarly, a study by Jouan et al. (2020) found a decrease in NKT and MAIT cells in the peripheral blood of COVID-19 patients (n = 30, with varied disease severity) as compared to healthy controls (n = 20). |
T634 |
52837-53112 |
Sentence |
denotes |
This decline in circulating MAIT cells was concomitantly associated with an increase in these cells in the endotracheal aspirates (ETA) obtained from critically ill patients who needed mechanical ventilation (n = 12), while no changes in NKT cell number in ETA were detected. |
T635 |
53113-53272 |
Sentence |
denotes |
The presence of circulating IL-18 reflected the activation of these cells, and the expression of PD-1 suggested subsequent exhaustion throughout the infection. |
T636 |
53273-53430 |
Sentence |
denotes |
This study thus indicates that the presence of the activated status of these unconventional T cells may serve as a predictive assessment of disease severity. |
T637 |
53431-53666 |
Sentence |
denotes |
More research about the activation, proliferation and differentiation status of these cells to the disease severity and local vs systemic effect is needed to fully understand their contribution in COVID-19 (Chen and John Wherry, 2020). |
T638 |
53668-53699 |
Sentence |
denotes |
Lymphocytopenia During COVID-19 |
T639 |
53700-53976 |
Sentence |
denotes |
A drastic decrease in the number of circulating lymphocytes (lymphocytopenia) in severe and critically ill COVID-19 patients is now well appreciated (Huang C. et al., 2020; Liao et al., 2020; Liu et al., 2020a; Mathew et al., 2020; Zhou F. et al., 2020; Zhou P. et al., 2020). |
T640 |
53977-54103 |
Sentence |
denotes |
Interestingly, restoration in the lymphocyte count is also consistently seen during the recovery phase (Chen Y. et al., 2020). |
T641 |
54104-54240 |
Sentence |
denotes |
Based on these early findings, lymphocytopenia is considered a predictive indicator of COVID-19 disease severity (Tan L. et al., 2020b). |
T642 |
54241-54459 |
Sentence |
denotes |
Although the molecular mechanisms associated with lymphocytopenia during SARS-CoV-2 are not known, emerging evidence suggests the role of multiple factors based on the correlations drawn from previous viral infections. |
T643 |
54460-54788 |
Sentence |
denotes |
The decline in lymphocyte numbers in circulation can be attributed to altered chemokine and cytokine signaling responsible for the recruitment and activation/inhibition of these cells, increased infiltration to the site of infection, and cell death by apoptosis and/or necrosis (Wherry and Kurachi, 2015; Walling and Kim, 2018). |
T644 |
54789-54975 |
Sentence |
denotes |
Immune profiles of COVID-19 patients show adequate levels of chemokines and cytokines involved in the maintenance of T and B cell phenotypes (Yang X. et al., 2020; Yang Y. et al., 2020). |
T645 |
54976-55088 |
Sentence |
denotes |
Chemokines and cytokines responsible for CD8+ T cells priming and chemotaxis were also detected in the patients. |
T646 |
55089-55319 |
Sentence |
denotes |
Similarly, cytokines responsible for B cell activation and proliferation signals were sufficiently present, thus excluding the possibility that lymphocytopenia may be a result of impaired activation signals or chemokine signaling. |
T647 |
55320-55547 |
Sentence |
denotes |
Interestingly, a recent study suggests that severely ill COVID-19 patients had lower levels of activated (CD11a+) and terminally differentiated (CD57+) peripheral blood CD4+ and CD8+ T cells (which are also S-protein reactive). |
T648 |
55548-55686 |
Sentence |
denotes |
The decline in the number of these cells can attribute to their concomitant migration to the infected regions under inflammatory response. |
T649 |
55687-55881 |
Sentence |
denotes |
Similarly, another study has shown lymphocytopenia in peripheral blood along with a concomitant increase in the activation profile and the number of these cells in the lungs (Song et al., 2020). |
T650 |
55882-56038 |
Sentence |
denotes |
Homing of these activated T cells to the site of infection may thus be associated with the worsening of the disease by amplifying the proinflammatory state. |
T651 |
56039-56141 |
Sentence |
denotes |
A single patient analysis revealed increased CD4+ and CD8+ T cells in the BALF (Voiriot et al., 2020). |
T652 |
56142-56353 |
Sentence |
denotes |
ScRNA-seq in BALF followed by cluster analysis revealed the presence of CD8+ T cells with proliferative phenotype in severe cases, whereas moderate cases exhibited clonal expansion phenotype (Liao et al., 2020). |
T653 |
56354-56630 |
Sentence |
denotes |
From these accounts, it is indicative that increased migration of activated T cells to the site of infection may be one of the reasons for lymphocytopenia (in the blood) and the remaining T cells in the blood may eventually become dysfunctional (exhausted) as discussed below. |
T654 |
56631-56785 |
Sentence |
denotes |
The decline in circulating lymphocyte number in COVID-19 patients can also attribute to the ‘exhausted’ state of these cells (Chen and John Wherry, 2020). |
T655 |
56786-56955 |
Sentence |
denotes |
The heightened viral load and presence of specific inhibitory signals bring about changes in the transcriptional and effector profile of T cells in a coordinated manner. |
T656 |
56956-57151 |
Sentence |
denotes |
Initially, they lose their property to secrete effector cytokines and gradually proceed to reduced expression of essential maintenance and activation surface receptors (Wherry and Kurachi, 2015). |
T657 |
57152-57342 |
Sentence |
denotes |
A subsequent increase in the expression of inhibitory receptors and associated morphological changes result in the elimination of these cells from the circulation (Wherry and Kurachi, 2015). |
T658 |
57343-57618 |
Sentence |
denotes |
CD4+ T cell exhaustion determines their insufficient secretion of effector molecules like IL-2, IL-10, IL-21, IFN-γ and TNF-α with a concomitant increase in inhibitory molecular signaling by PD-1, CTLA-4, LAG-3, CD244 (2B4), and TIM-3 (Blank et al., 2019; Dong et al., 2019). |
T659 |
57619-57735 |
Sentence |
denotes |
Similarly, CD8+ T cell exhaustion is determined by reduced expression of IL-2, IFN-γ, TNF-α, and cytolytic granules. |
T660 |
57736-57997 |
Sentence |
denotes |
Besides, decreased expression of T cell maintenance receptors CD122 and CD127, and increase in inhibitory receptor signaling via PD-1, CTLA-4, NKG2A, TIGIT, LAG-3, CD244 (2B4), and CD160 also mark their exhaustion (Wherry and Kurachi, 2015; Blank et al., 2019). |
T661 |
57998-58222 |
Sentence |
denotes |
B cell exhaustion is also demonstrated similar to T cell exhaustion with an expression of inhibitory receptors PD-1, CD22, and LAIR-1 but the exhaustion profile of these cells is relatively unexplored (Moir and Fauci, 2014). |
T662 |
58223-58351 |
Sentence |
denotes |
A large body of evidence suggests functional exhaustion of CD8+ T and CD4+ T cells in the peripheral blood of COVID-19 patients. |
T663 |
58352-58549 |
Sentence |
denotes |
In some instances, exhaustion markers are concomitantly expressed along with activation and proliferation markers, as discussed above (Diao et al., 2020; Mathew et al., 2020; Mazzoni et al., 2020). |
T664 |
58550-58697 |
Sentence |
denotes |
Moreover, increased expression of exhaustion-related genes like BATF, IRF4, and CD274 also correlated with disease severity (Hadjadj et al., 2020). |
T665 |
58698-58815 |
Sentence |
denotes |
Interestingly, increased apoptosis of T cells became evident in severe cases as compared to mild/moderate conditions. |
T666 |
58816-58960 |
Sentence |
denotes |
Thus, one way to explain lymphocytopenia in COVID-19 patients is that after the onset of symptoms, T cells are primed to overcome the infection. |
T667 |
58961-59169 |
Sentence |
denotes |
However, in cases where viral infection persists, these cells attain robust activation, which may do more harm than good, as seen in severe and critically ill patients reviewed by Chen and John Wherry (2020). |
T668 |
59170-59384 |
Sentence |
denotes |
Thus, the exhaustion of these cells precedes robust activation response, and eventually, they get eliminated from the circulation, as has been seen with previous viral infections (Wherry, 2011; Blank et al., 2019). |
T669 |
59385-59563 |
Sentence |
denotes |
For example, during acute infection by lymphocytic choriomeningitis virus (LCMV), CD8+ T cells were shown to exhibit functional activation status and develop into memory T cells. |
T670 |
59564-59746 |
Sentence |
denotes |
In contrast, during chronic infection, CD8+ T cells had impaired effector function and displayed profound exhaustion followed by apoptosis (Barber et al., 2006; Wherry et al., 2007). |
T671 |
59747-59961 |
Sentence |
denotes |
Similarly, CD8+ T cell exhaustion is well known during persistent human immunodeficiency virus (HIV) infection, marked by robust expression of exhaustion markers like PD-1 (Day et al., 2006; Petrovas et al., 2006). |
T672 |
59962-60135 |
Sentence |
denotes |
Following exhaustion, these cells are eliminated from the circulation, which is responsible for the decline in their number with long-term infection (Petrovas et al., 2009). |
T673 |
60136-60425 |
Sentence |
denotes |
In addition to transcriptional changes that lead to exhaustion during chronic viral infection, the presence of secretory inhibitory molecules has been implicated in lymphocyte exhaustion with a prominent role of IL-10 and TGF-β in CD8+ T cell exhaustion (Wherry, 2011; Blank et al., 2019). |
T674 |
60426-60581 |
Sentence |
denotes |
Increased levels of these cytokines in COVID-19 patients may also suggest their potential role in CD8+ T cell exhaustion (Chen, 2020; Liu A. et al., 2020). |
T675 |
60582-60743 |
Sentence |
denotes |
Furthermore, severe COVID-19 patients had elevated lactic acid levels which is a known inhibitor of T cell function (Fischer et al., 2007; Tan L. et al., 2020b). |
T676 |
60744-60836 |
Sentence |
denotes |
Another vital aspect of lymphocytopenia is direct cell death by the virus during infections. |
T677 |
60837-60979 |
Sentence |
denotes |
HIV is a well-known example wherein CD4+ T cells undergo activation-induced cell death by the virus (Day et al., 2006; Petrovas et al., 2009). |
T678 |
60980-61111 |
Sentence |
denotes |
Though respiratory viruses are not known to induce T cell apoptosis directly, virus-activated secondary factors may be responsible. |
T679 |
61112-61267 |
Sentence |
denotes |
For example, T cell apoptosis was seen by the enhanced expression of death receptors during the infection of influenza virus (H5N1) (Boonnak et al., 2014). |
T680 |
61268-61474 |
Sentence |
denotes |
MERS infection was also associated with T cell apoptosis by the virus-mediated activation of intrinsic and extrinsic pathways of cell death, resulting in their depletion from circulation (Chu et al., 2014). |
T681 |
61475-61577 |
Sentence |
denotes |
The MERS infection was abortive in these cells, suggesting indirect activation of cell death pathways. |
T682 |
61578-61741 |
Sentence |
denotes |
A few in vitro studies have shown low replication of SARS-CoV in T cells and the absence of any significant cell death (Chan and Chen, 2008; Wang X. et al., 2020). |
T683 |
61742-61939 |
Sentence |
denotes |
Whether SARS-CoV-2 infects, T cells are currently unknown, but it appears that T cell decline during COVID-19 cannot be attributed to direct cell death by the virus but to the exhaustion mechanism. |
T684 |
61940-62296 |
Sentence |
denotes |
In addition to the mechanism mentioned above associated with lymphocytopenia, secondary signaling mediated via engagement of death receptors, increased ROS, HMGB1 and other death-inducing agents released by the infected and damaged ATII cells may also be implicated in T cell decline (Kaminskyy and Zhivotovsky, 2010; Juno et al., 2017; Zhan et al., 2017). |
T685 |
62297-62508 |
Sentence |
denotes |
Thus, based on these early findings, lymphocyte exhaustion may be driven by multiple factors that actively engage in rendering these cells ineffective, followed by their subsequent elimination (lymphocytopenia). |
T686 |
62509-62641 |
Sentence |
denotes |
Overall, a clear picture is emerging, which strongly indicates lymphocytopenia as a predictive marker for COVID-19 disease severity. |
T687 |
62642-62861 |
Sentence |
denotes |
Along with increased neutrophil number, the blood lymphocyte count serves as a better prognostic marker and reflects the immunopathological state of the patients (Giamarellos-Bourboulis et al., 2020; Liu et al., 2020b). |
T688 |
62862-62991 |
Sentence |
denotes |
Further, based on these emerging studies, it is becoming evident that T cell response is heterogeneous during COVID-19 infection. |
T689 |
62992-63212 |
Sentence |
denotes |
While peripheral blood may exhibit lymphocytopenia, and mostly exhausted status of these cells, the site of infection is associated with an activated profile of the cells and hence determines the severity of the disease. |
T690 |
63213-63302 |
Sentence |
denotes |
Thus, caution should be exercised while designing therapeutic interventions for COVID-19. |
T691 |
63303-63394 |
Sentence |
denotes |
The underlying immunological state should be borne in mind while considering the treatment. |
T692 |
63395-63612 |
Sentence |
denotes |
Patients with lymphocytopenia and elevated functional and activation status of T cells may benefit from immunomodulatory approaches like mesenchymal stem cells, which are currently under clinical trials (NCT04377334). |
T693 |
63613-63832 |
Sentence |
denotes |
Patients with imperfect T cell and B cell responses may benefit from convalescent plasma therapy, whereas patients with impaired interferon response may respond better to interferon therapies (NCT04350671; NCT04388709). |
T694 |
63833-63999 |
Sentence |
denotes |
Thus, before a vaccine is available, a rational way to recommend therapy for severe cases of COVID-19 should be based on the patient’s underlying immunological state. |
T695 |
64000-64111 |
Sentence |
denotes |
However, the treatment options become challenging when the patients exhibit cytokine storm and associated ARDS. |
T696 |
64112-64315 |
Sentence |
denotes |
Moreover, it is imperative to analyze the T and B cell response by considering the age of the patient, comorbid condition, severity score, time of sample collection, and the method used for the analysis. |
T697 |
64316-64526 |
Sentence |
denotes |
Because, the adaptive immune response is highly sensitive to these factors, and undermining them may thus further complicate our understanding of the development of the immunopathological state during COVID-19. |